NASDAQ:CMPX Compass Therapeutics Q2 2024 Earnings Report $1.90 -0.06 (-2.82%) As of 10:05 AM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Compass Therapeutics EPS ResultsActual EPS-$0.10Consensus EPS -$0.10Beat/MissMet ExpectationsOne Year Ago EPSN/ACompass Therapeutics Revenue ResultsActual Revenue$0.85 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ACompass Therapeutics Announcement DetailsQuarterQ2 2024Date8/12/2024TimeBefore Market OpensConference Call DateMonday, August 12, 2024Conference Call Time8:00AM ETUpcoming EarningsCompass Therapeutics' Q2 2026 earnings is estimated for Thursday, May 14, 2026, based on past reporting schedulesConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Compass Therapeutics Earnings HeadlinesCanaccord Maintains Buy Rating on Compass Therapeutics (CMPX)May 5 at 9:45 AM | finance.yahoo.comCompass Therapeutics Reports 2026 First Quarter Financial Results and Provides Corporate UpdateMay 5 at 7:30 AM | globenewswire.comA U.S. Resource Gap Is a National Issue - and OpportunityAmerica still does not domestically produce one mineral tied to batteries, energy storage, and national defense - and that supply gap may be turning into an opportunity. One domestic supplier appears to have identified that gap early and moved to capitalize on it before the broader market took notice.May 6 at 1:00 AM | i2i Marketing Group, LLC (Ad)Canaccord Genuity Group Cuts Compass Therapeutics (NASDAQ:CMPX) Price Target to $7.00May 1, 2026 | americanbankingnews.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPXApril 30, 2026 | prnewswire.comDoes Compass Therapeutics' (CMPX) Biliary Cancer Data Hint At A Broader Pipeline Re‑Rating Opportunity?April 29, 2026 | finance.yahoo.comSee More Compass Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Compass Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Compass Therapeutics and other key companies, straight to your email. Email Address About Compass TherapeuticsCompass Therapeutics (NASDAQ:CMPX) is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment. The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells. Both assets have advanced into clinical development, with ongoing studies evaluating safety, pharmacodynamics and preliminary efficacy across multiple tumor types. Compass also maintains a rich preclinical pipeline of next‐generation antibody constructs designed to address checkpoint resistance and immune suppression in solid tumors. Compass Therapeutics employs an integrated discovery and development model, combining in‐house antibody engineering capabilities with translational science and biomarker analysis. The company collaborates with academic institutions and contract research organizations to streamline the advancement of its molecules from lead optimization through early‐phase clinical trials. This approach supports rapid iteration and selection of candidates with differentiated mechanisms of action. Founded in 2018, Compass Therapeutics is led by President and Chief Executive Officer Ravi Mohan, Ph.D., whose experience spans immuno-engineering and oncology drug development. While primarily focused on the U.S. market, the company is positioned to pursue global clinical collaborations and strategic partnerships as its clinical programs mature.View Compass Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Just How Big a Problem Could Amazon’s Cash Burn Rate Be?BlackBerry Rewrites Its Own Operating SystemGrab Holdings Faces Hurdles, But Upside Potential Is Hard to IgnorePalantir Drops After a Blowout Q1—What Investors Should KnowShopify’s Valuation Crisis Creates Opportunity in 2026onsemi Stock Dips After Earnings: Why the Dip Is BuyableTSLA: 3 Reasons the Stock Could Hit $400 in May Upcoming Earnings Coinbase Global (5/7/2026)Airbnb (5/7/2026)Datadog (5/7/2026)Ferrovial (5/7/2026)Gilead Sciences (5/7/2026)Microchip Technology (5/7/2026)MercadoLibre (5/7/2026)Monster Beverage (5/7/2026)Canadian Natural Resources (5/7/2026)W.W. Grainger (5/7/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
